Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8924401 | 0.76 | KMT2A (0.67) | ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL19294513 | 0.71 | ALDH1A1 (0.50) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16534452 | 0.70 | MEN1 (0.62) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15285510 | 0.70 | MEN1 (0.62) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15285704 | 0.70 | RECQL (0.78) | ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL15285655 | 0.70 | GBA1 (0.67) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2959883 | 0.70 | MAPT (0.66) | ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL23420014 | 0.69 | TP53 (0.64) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15285581 | 0.69 | MAPT (0.74) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15285394 | 0.69 | MAPT (0.67) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034078-A1 | XPG INHIBITOR COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | FUND D ANNA DE SOMMER CHAMPALIMAUD E DR CARLOS MONTEZ CHAMPALIMAUD (PT) | 2026-02-05 | — | — | US | claimed |
| EP-4686475-A1 | XPG INHIBITORS FOR USE IN THE TREATMENT OF CANCER | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD - CENTRO DE INVESTIGAÇÃO DA FUNDAÇÃO CHAMPALIMAUD (PT) | 2026-02-04 | — | — | EP | claimed |
| US-20260034078-A1 | XPG INHIBITOR COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | FUND D ANNA DE SOMMER CHAMPALIMAUD E DR CARLOS MONTEZ CHAMPALIMAUD (PT) | 2026-02-05 | — | — | US | disclosed |
| EP-4686475-A1 | XPG INHIBITORS FOR USE IN THE TREATMENT OF CANCER | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD - CENTRO DE INVESTIGAÇÃO DA FUNDAÇÃO CHAMPALIMAUD (PT) | 2026-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034078-A1 | XPG INHIBITOR COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | XPOT, XPO1, XPA | ALDH1A1 4396/4885LMNA 1845/4885SMN1; SMN2 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.